TrianglePUBLICATIONS · 19114704
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2009 Feb 10
- First author
- Kreisl TN
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Kreisl TN
- type
- Author
- name
- Kim L
- type
- Author
- name
- Moore K
- type
- Author
- name
- Duic P
- type
- Author
- name
- Royce C
- type
- Author
- name
- Stroud I
- type
- Author
- name
- Garren N
- type
- Author
- name
- Mackey M
- type
- Author
- name
- Butman JA
- type
- Author
- name
- Camphausen K
- type
- Author
- name
- Park J
- type
- Author
- name
- Albert PS
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Kreisl TN
- type
- Author
- name
- Kim L
- type
- Author
- name
- Moore K
- type
- Author
- name
- Duic P
- type
- Author
- name
- Royce C
- type
- Author
- name
- Stroud I
- type
- Author
- name
- Garren N
- type
- Author
- name
- Mackey M
- type
- Author
- name
- Butman JA
- type
- Author
- name
- Camphausen K
- type
- Author
- name
- Park J
- type
- Author
- name
- Albert PS
- type
- Author
- bibliography ids
- nci-bib-820a0c1d5b89172c8e0b8e08
- book metadata
- content sha256
- 2a041040907ef989f437f2180f19b5d4190b6b9eb6302a7fa57f1324dca8c6e9
- document type
- citation
- dois
- 10.1200/JCO.2008.16.3055
- electronic publication date
- display
- 2008 Dec 29
- precision
- day
- year
- 2008
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:19114704
- immutable id
- pubmed:19114704@2a041040907ef989f437f2180f19b5d4190b6b9eb6302a7fa57f1324dca8c6e9
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 5
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 740-5
- volume
- 27
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 19114704
- provenance
- batch id
- 27a383f06e5fc3d04fad
- provider
- NCBI PubMed ESummary
- record sha256
- 383fd9d43d8a5da95e543feed18d258b6c6057f524806cfab801ef3aa059c155
- response sha256
- 51f0f2a142dbd9b135e872b049b116f51941299445a5416feae10f12fac8d978
- retrieved at
- 2026-09-09T23:46:24.265787+00:00
- publication date
- display
- 2009 Feb 10
- precision
- day
- year
- 2009
- publication types
- Clinical Trial, Phase II
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Preserved source evidence · Not medical advice